Journal of Avian Medicine and Surgery · 2004 · 52 citations · 23 references
PharmacyPharmacokineticsPharmacologyBioavailabilityGeneral PharmacologyNoncompartmental AnalysisAnalgesic PharmacologyDrug DispositionOpioid PharmacologyAnalgesia In BirdsAvian PharmacologyDrug Elimination Half-lifeNoncompartmental Analysis SamplingNoncompartmental Distribution AnalysisPharmacokinetics Of AnalgesicsResidence TimeVeterinary Pharmacokinetics
Buprenorphine is a synthetic mixed agonist-antagonist opiate analgesic that is used in a variety of species. To determine if a dose of buprenorphine at 0.1 mg/kg achieves plasma concentrations in parrots that would be analgesic in humans (0.5–1.0 ng/ml), we administered a single dose of buprenorphine (at 0.1 mg/kg) either intramuscularly (5 birds) or intravenously (1 bird) to African grey parrots (Psittacus erithacus erithacus). Serial plasma samples were taken before and at 0.25, 0.5, 0.75, 1.0, 1.5, 2, 6, and 8 hours after administration. For a single intramuscular dose, buprenorphine was rapidly absorbed, and plasma concentrations had a mean residence time of 1.0 hour, elimination half-life of 1.0 hour, and maximum concentration of 68.7 ng/ml, determined by using noncompartmental analysis. This dose of buprenorphine can achieve plasma levels for at least 2 hours in the African grey parrot for comparable analgesic levels in humans, however buprenorphine is not recommended as an analgesic treatment for parrots until pharmacokinetic and analgesia studies are done at higher doses.
23
The metabolism and excretion of buprenorphine in humans.
Edward J. Cone, Charles W. Gorodetzky, David Yousefnejad et al. · Drug Metabolism and Disposition · 1984 · 224 citations
Roy Bullingham, Henry J McQuay, Andrew Moore et al. · Clinical Pharmacology & Therapeutics · 1980 · 168 citations
M Ohtani, H. Kotaki, Yasufumi Sawada et al. · Journal of Pharmacology and Experimental Therapeutics · 1995 · 157 citations